Mining the mechanisms of an HIV vaccine

Nature Medicine

Volumn 18, Issue 7, 2012, Pages 1021-

  Robinson, Harriet L ^a   Davenport, Miles P ^b  

^a Research and Development   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; TREATMENT OUTCOME;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TREATMENT OUTCOME;

EID: 84988042464     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2858     Document Type: Article

References (11)

1. Haynes, B.F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
2. Plotkin, S.A. & Gilbert, P.B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615–1617 (2012).
3. Grove, J. & Marsh, M. The cell biology of receptor-mediated virus entry. J. Cell Biol. 195, 1071–1082 (2011).
4. Walker, L.M. & Burton, D.R. Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr. Opin. Immunol. 22, 358–366 (2010).
5. Hansen, S.G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527 (2011).
6. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
7. Burton, D.R. et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 303, 316 (2004).
8. Burton, D.R. et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. USA 108, 11181–11186 (2011).
9. Doria-Rose, N.A. et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 86, 3393–3397 (2012).
10. Gilbert, P.B. et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191, 666–677 (2005).
11. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).